Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2014 - 2026)

Jazz Pharmaceuticals' Long-Term Investments history runs 12 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 45.07% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 45.07% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 81.03% from the prior year.
• Long-Term Investments eased to $1.0 billion in Q1 2026 per JAZZ's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.0 billion in Q4 2025 and bottomed at $60.0 million in Q2 2022.
• The 5-year median for Long-Term Investments is $440.0 million (2024), against an average of $467.1 million.
• Across the five-year window, Long-Term Investments surged 681.25% in 2024 and declined 23.2% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $60.0 million in 2022, then soared by 100.0% to $120.0 million in 2023, then surged by 383.33% to $580.0 million in 2024, then soared by 81.03% to $1.0 billion in 2025, then fell by 1.9% to $1.0 billion in 2026.
• Per Business Quant, the three latest JAZZ Long-Term Investments figures stand at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $720.0 million (Q3 2025).